Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Pharmacology  





2 Uses  





3 References  





4 External links  














Sulodexide






Italiano
Polski
Português
Română
Српски / srpski
Srpskohrvatski / српскохрватски
Українська
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Sulodexide
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral, Subcutaneous, Intravenous, Intramuscular
ATC code
Identifiers
  • Glucurono-2-amino-2-deoxyglucoglucan sulfate

CAS Number
DrugBank
UNII
KEGG
  (verify)

Sulodexide, traded as Aterina, is a highly purified mixture of glycosaminoglycans composed of heparan sulfate (80%) and dermatan sulfate (20%).

Pharmacology

[edit]

The low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated heparin. The pharmacological effects of sulodexide differ substantially from other glycosaminoglycans and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters.[1] Due to the presence of both glycosaminoglycan fractions, sulodexide potentiates the antiprotease activities of both antithrombin III and heparin cofactor II simultaneously.[2]

Uses

[edit]

Clinically, sulodexide is used for the prophylaxis and treatment of thromboembolic diseases. Research has also demonstrated the beneficial effects of sulodexide in animal models of reperfusion injury[3] and the treatment of diabetic nephropathy.[4][5][6] In combination with melatonin, sulodexide has been shown to be a viable treatment option for patients suffering from central or sensorineural tinnitus.[7][8] There have also been positive results in treating tinnitus using sulodexide as a monotherapy.[9] Sulodexide has also been effectively used in the treatment of chronic venous disease.[10]

References

[edit]
  1. ^ Lauver DA, Lucchesi BR (2006). "Sulodexide: a renewed interest in this glycosaminoglycan". Cardiovascular Drug Reviews. 24 (3–4): 214–226. doi:10.1111/j.1527-3466.2006.00214.x. hdl:2027.42/73024. PMID 17214598.
  • ^ Harenberg J (January 1998). "Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide". Medicinal Research Reviews. 18 (1): 1–20. doi:10.1002/(SICI)1098-1128(199801)18:1<1::AID-MED1>3.0.CO;2-4. PMID 9436179. S2CID 26366651.
  • ^ Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR (February 2005). "Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis". The Journal of Pharmacology and Experimental Therapeutics. 312 (2): 794–800. doi:10.1124/jpet.104.075283. PMID 15365091. S2CID 9865911.
  • ^ Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M (2005). "One year course of oral sulodexide in the management of diabetic nephropathy". Journal of Nephrology. 18 (5): 568–574. PMID 16299683.
  • ^ Gambaro G, Venturini AP, Noonan DM, Fries W, Re G, Garbisa S, et al. (September 1994). "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy". Kidney International. 46 (3): 797–806. doi:10.1038/ki.1994.335. PMID 7527876.
  • ^ Skrha J, Perusicová J, Pont'uch P, Oksa A (October 1997). "Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients". Diabetes Research and Clinical Practice. 38 (1): 25–31. doi:10.1016/S0168-8227(97)00076-4. PMID 9347243.
  • ^ Neri G, Baffa C, De Stefano A, Poliandri A, Kulamarva G, Di Giovanni P, et al. (2009). "Management of tinnitus: oral treatment with melatonin and sulodexide". Journal of Biological Regulators and Homeostatic Agents. 23 (2): 103–110. PMID 19589291.
  • ^ Neri G. De Stefano A. Baffa C. Kulamarva G. Di Giovanni P. Petrucci G. Poliandri A. Dispenza F. Citraro L. Croce A. ,"Treatment of central and sensorineural tinnitus with orally administered Melatonin and Sulodexide: personal experience from a randomized controlled study." Acta Otorhinolaryngologica Italica. 29(2):86-91, 2009 Apr.
  • ^ El Beaino M, McCaskey MK, Eter E (June 2018). "Sulodexide Monotherapy in Chronic Idiopathic Subjective Tinnitus: A Randomized Controlled Trial". Otolaryngology–Head and Neck Surgery. 158 (6). SAGE Publications: 1107–1112. doi:10.1177/0194599818767618. PMID 29712507. S2CID 14058842.
  • ^ Andreozzi GM (April 2012). "Sulodexide in the treatment of chronic venous disease". American Journal of Cardiovascular Drugs. 12 (2): 73–81. doi:10.2165/11599360-000000000-00000. PMID 22329592. S2CID 23046029.
  • [edit]


  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Sulodexide&oldid=1193267344"

    Categories: 
    Glycosaminoglycans
    Blood and blood forming organ drug stubs
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Infobox drug articles without a structure image
    Articles without EBI source
    Chemical pages without ChemSpiderID
    Articles without InChI source
    Drugs with no legal status
    All stub articles
     



    This page was last edited on 2 January 2024, at 22:58 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki